StockData
Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc. (PLRX) stock

PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$0.66−0.03 (-4.76%)

Close on Nov 17, 2026Market cap $40.88MP/E –Yield 0.00%

Pliant Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Pliant Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$97.48M. For fiscal 2025 it was -$156.37M. The highest annual figure on record is -$1.23M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$156.37M–
FY2024Dec 31, 2024-$228.37M–
FY2023Dec 31, 2023-$184.15M–
FY2022Dec 31, 2022-$127.20M–
FY2021Dec 31, 2021-$97.54M–
FY2020Dec 31, 2020-$41.65M–
FY2019Dec 31, 2019-$1.23M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.86M–
Q1 FY2026Mar 31, 2026-$21.77M–
Q4 FY2025Dec 31, 2025-$23.58M–
Q3 FY2025Sep 30, 2025-$28.27M–
Q2 FY2025Jun 30, 2025-$45.59M–
Q1 FY2025Mar 31, 2025-$58.94M–
Q4 FY2024Dec 31, 2024-$53.32M–
Q3 FY2024Sep 30, 2024-$62.01M–
Q2 FY2024Jun 30, 2024-$60.64M–
Q1 FY2024Mar 31, 2024-$52.39M–
Q4 FY2023Dec 31, 2023-$47.04M–
Q3 FY2023Sep 30, 2023-$47.69M–
Q2 FY2023Jun 30, 2023-$47.33M–
Q1 FY2023Mar 31, 2023-$42.10M–
Q4 FY2022Dec 31, 2022-$37.40M–
Q3 FY2022Sep 30, 2022-$31.95M–
Q2 FY2022Jun 30, 2022-$29.64M–
Q1 FY2022Mar 31, 2022-$28.21M–
Q4 FY2021Dec 31, 2021-$24.60M–
Q3 FY2021Sep 30, 2021-$27.11M–
Q2 FY2021Jun 30, 2021-$22.90M–
Q1 FY2021Mar 31, 2021-$22.92M-308.2%
Q4 FY2020Dec 31, 2020-$19.02M-145.0%
Q3 FY2020Sep 30, 2020-$16.66M–
Q2 FY2020Jun 30, 2020-$16.98M–
Q1 FY2020Mar 31, 2020$11.01M–
Q4 FY2019Dec 31, 2019$42.22M–
Q3 FY2019Sep 30, 2019-$13.36M–
Q2 FY2019Jun 30, 2019-$15.74M–

More Pliant Therapeutics figures

See a number that looks wrong?